Navigation Links
Medivation Announces Publication in The Lancet of Dimebon Pivotal Trial Results in Alzheimer's Disease
Date:7/17/2008

to see our first pivotal trial culminate with publication of its significant findings in such a prestigious journal," said David Hung, M.D., President and Chief Executive Officer of Medivation. "Currently available therapies treat the symptoms of Alzheimer's disease with only modest effect. The Dimebon study is the first study in which a drug has achieved statistically significant benefits of this breadth, size and duration in a one year, well-controlled trial. These data, coupled with our recently announced positive results in Huntington's disease, suggest that Dimebon could be a novel therapy for the treatment of neurodegenerative diseases. We look forward to the completion of our confirmatory pivotal Phase 3 study of Dimebon in Alzheimer's disease."

About the Pivotal Study

In the trial, 183 patients with mild-to-moderate Alzheimer's disease were randomized to receive Dimebon (20 mg three times a day, administered orally) or placebo for six months. 134 patients continued treatment in a blinded manner for an additional six months (one year total treatment) in the same group to which they were originally randomized; 120 of these patients (90 percent) completed the trial.

Earlier this year, the U.S. Food and Drug Administration (FDA) informed Medivation that this study can be used as one of the pivotal studies required to support the approval of Dimebon to treat mild-to-moderate Alzheimer's disease, as long as a significant proportion of the sites in the confirmatory Phase 3 trial are located in the United States. The Company recently began a confirmatory pivotal Phase 3 trial of Dimebon in Alzheimer's disease known as the CONNECTION study. Patients and caregivers can learn more about the study by visiting http://www.connectionstudy.com or by calling 1-877-888-6386.

About Dimebon

Dimebon is an orally available small molecule that has been shown to inhibit brain cell death in
'/>"/>

SOURCE Medivation, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Medivation Announces Positive Top-Line Results From Phase 2 Dimebon Study in Huntingtons Disease
2. Medivation to Host Conference Call at 5 p.m. EDT Monday to Discuss Top-Line Phase 2 Study Results in Huntingtons Disease
3. Medivation Initiates Second Pivotal Phase 3 Trial of Dimebon(TM) in Patients With Alzheimers Disease
4. Medivation Announces Presentation of Positive MDV3100 Clinical Data in Castration-Resistant Prostate Cancer Patients at 44th ASCO Annual Meeting
5. Medivation Announces Presentation of MDV3100 Clinical Data in Patients With Castration-Resistant Prostate Cancer at 44th American Society of Clinical Oncology Annual Meeting
6. Medivations Dimebon(TM) Significantly Improved Thinking and Memory in Alzheimers Disease Patients Over One Year
7. Medivations Dimebon(TM) Significantly Improved Daily Function in Alzheimers Disease Patients, Resulting in Reduced Need for Caregiver Assistance
8. Medivations Dimebon(TM) Stabilizes Behavioral Symptoms in Alzheimers Disease Patients, Resulting in Reduced Caregiver Distress
9. Medivations MDV3100 Demonstrates Substantial PSA Reductions in First Patient Groups Treated in Phase 1-2 Hormone Refractory Prostate Cancer Trial
10. Vical Announces Breakthrough for Pandemic Influenza DNA Vaccines With Preliminary Human Data
11. Biodel Inc. Announces the Completion of Its Two Pivotal Trials and the Release of EASD Abstracts Containing Additional Interim Data From Its VIAject(TM) Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 15, 2014 As health officials across the Midwest warn ... pharmacies in Michigan will offer free ... enabling Meijer pharmacists to administer tests and, in some cases, ... physician participating in the study. The ...
(Date:1/15/2014)... 2014  Novation, the leading health care supply chain expertise, ... reseller (VAR) national contracts that expand its portfolio to ... lower costs. These include manufacturer product and service agreements, ... and ongoing IT consulting support. New ...
(Date:1/15/2014)... , Jan. 15, 2014 Massachusetts General ... AMGN ) announced today that they ... and validate new therapeutic targets and develop novel ... disorder that affects millions worldwide. The MGH-Broad-Amgen collaboration ...
Breaking Medicine Technology:Meijer Pharmacy Offers Free Flu, Strep Testing as Influenza Cases Rise Across the Midwest 2Meijer Pharmacy Offers Free Flu, Strep Testing as Influenza Cases Rise Across the Midwest 3New Novation Information Technology VAR Contracts Offer Significant Savings to Hospitals 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 4
... Partners announced today that it has updated coverage ... Analyst at Vista Partners stated, "Raptor is potentially a ... balanced pipeline of clinical and preclinical programs.  The Company ... and one Phase 3 trial with some indications in ...
... Sept. 15 Masimo (Nasdaq: ... of Health, Labor and Welfare (MHLW) regulatory clearance ... available as part of the Masimo rainbow SET® ... continuously measuring a patient,s hemoglobin level in real-time, ...
Cached Medicine Technology:Masimo Noninvasive and Continuous Hemoglobin Receives Market Clearance in Japan 2Masimo Noninvasive and Continuous Hemoglobin Receives Market Clearance in Japan 3Masimo Noninvasive and Continuous Hemoglobin Receives Market Clearance in Japan 4
(Date:7/9/2014)... is for more than watching World Cup highlights, Brian ... skateboarders landing in unfortunate positions on railings. A University ... Dermatology Online Journal shows that YouTube also allows ... the public on topics of skin cancer and prevention. ... is the future of how we communicate around the ...
(Date:7/9/2014)... retrospective study conducted by researchers at Tufts University School ... with intellectual and developmental disabilities, the likelihood of having ... care increased. The findings, published in the July/August issue ... improve interventions designed to address the oral health of ... the dental records of 107 patients at one of ...
(Date:7/9/2014)... A study published in the scientific journal Nature ... two researchers at Universit Laval, reveals that it is ... that involves rekindling pain so that it can subsequently ... to alleviate chronic pain. , The researchers from the ... en sant mentale de Qubec (IUSMQ) were inspired by ...
(Date:7/8/2014)... Program in Memory Restoration has been awarded up to ... (DARPA) for a four -year project aiming to help ... of experts in neurosurgery, engineering, neurobiology, psychology and physics ... memory prosthesis in the brain. , Memory is the ... brain encode information, store it and retrieve it. Certain ...
(Date:7/8/2014)... In a study published yesterday in the scientific journal ... Institute (LJI) led by Pandurangan Vijayanand, Ph.D. identify new genes ... over 200 million people world wide. , An organism,s ... into small sections or ,neighborhoods., Scientists can determine which ... gene production, by looking for a marker on the genome ...
Breaking Medicine News(10 mins):Health News:Study of dermatology on YouTube shows new ways science reaches public 2Health News:Adults with special needs see gains, challenges with long term oral care 2Health News:Adults with special needs see gains, challenges with long term oral care 3Health News:Discovery of a new means to erase pain 2Health News:DARPA awards UCLA $15 million to restore lost memory 2Health News:DARPA awards UCLA $15 million to restore lost memory 3Health News:LJI develops new approach to identify genes poised to respond in asthma patients 2
... smokers say they,are likely to quit smoking because it is ... researchers. , The study, published Tuesday ... researchers looked at the smoking behaviors,of people who own or ... lived with a dog, cat or bird. , ...
... panel of pain-management experts representing the American Pain Society ... Pain Medicine (AAPM) has published the first comprehensive clinical ... pain medications for patients with chronic non-cancer pain. ... The Journal of Pain , www.jpain.org , ...
... PARI Respiratory Equipment launched two updated continuing ... with seven classes for respiratory therapists, nurses, case ... as group programs that are pre-approved for continuing ... Certification (CCMC), American Association of Respiratory Care (AARC), ...
... of Bio-IT World magazine, today announced the launch of a ... enterprise --www.ecliniqua.com. , ... Needham, MA ... publisher of Bio-IT World magazine, today announced the launch of ...
... use a new, cutting edge diagnostic technology to ... outcomes.WOBURN, Mass. and VEDBAEK, Denmark, Feb. 10 AdvanDx ... Rockford, Illinois has implemented AdvanDx,s PNA FISH(R) tests ... earlier than conventional methods to help their physicians, ...
... WESTFORD, Mass., Feb. 10 Cynosure, Inc. (Nasdaq: ... a broad array of light-based aesthetic treatment systems, today ... ended December 31, 2008. Fourth-Quarter 2008 Financial Results ... the three months ended December 31, 2008 were $25.5 ...
Cached Medicine News:Health News:Smokers Likely to Quit for Fido's Health, Not Their Own 2Health News:New guidelines for prescribing opioid pain drugs published 2Health News:New guidelines for prescribing opioid pain drugs published 3Health News:New guidelines for prescribing opioid pain drugs published 4Health News:PARI Respiratory Equipment Launches 2 New Continuing Ed Classes 2Health News:Cambridge Healthtech Media Group Launches Clinical Trials Web Site 2Health News:Cambridge Healthtech Media Group Launches Clinical Trials Web Site 3Health News:OSF Saint Anthony Medical Center Implements PNA FISH(R) Tests to Help Provide Best Care for Patients with Bloodstream Infections 2Health News:OSF Saint Anthony Medical Center Implements PNA FISH(R) Tests to Help Provide Best Care for Patients with Bloodstream Infections 3Health News:Cynosure Reports Financial Results for the Fourth Quarter and Full Year 2008 2Health News:Cynosure Reports Financial Results for the Fourth Quarter and Full Year 2008 3Health News:Cynosure Reports Financial Results for the Fourth Quarter and Full Year 2008 4Health News:Cynosure Reports Financial Results for the Fourth Quarter and Full Year 2008 5Health News:Cynosure Reports Financial Results for the Fourth Quarter and Full Year 2008 6Health News:Cynosure Reports Financial Results for the Fourth Quarter and Full Year 2008 7Health News:Cynosure Reports Financial Results for the Fourth Quarter and Full Year 2008 8Health News:Cynosure Reports Financial Results for the Fourth Quarter and Full Year 2008 9Health News:Cynosure Reports Financial Results for the Fourth Quarter and Full Year 2008 10Health News:Cynosure Reports Financial Results for the Fourth Quarter and Full Year 2008 11Health News:Cynosure Reports Financial Results for the Fourth Quarter and Full Year 2008 12Health News:Cynosure Reports Financial Results for the Fourth Quarter and Full Year 2008 13
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: